IBDEI39X ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,55016,0)
 ;;=C65.9^^256^2775^148
 ;;^UTILITY(U,$J,358.3,55016,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,55016,1,3,0)
 ;;=3^Malig Neop Renal Pelvis,Unspec
 ;;^UTILITY(U,$J,358.3,55016,1,4,0)
 ;;=4^C65.9
 ;;^UTILITY(U,$J,358.3,55016,2)
 ;;=^5001253
 ;;^UTILITY(U,$J,358.3,55017,0)
 ;;=C50.912^^256^2775^129
 ;;^UTILITY(U,$J,358.3,55017,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,55017,1,3,0)
 ;;=3^Malig Neop Left Female Breast,Unspec Site
 ;;^UTILITY(U,$J,358.3,55017,1,4,0)
 ;;=4^C50.912
 ;;^UTILITY(U,$J,358.3,55017,2)
 ;;=^5001196
 ;;^UTILITY(U,$J,358.3,55018,0)
 ;;=C50.911^^256^2775^151
 ;;^UTILITY(U,$J,358.3,55018,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,55018,1,3,0)
 ;;=3^Malig Neop Right Female Breast,Unspec Site
 ;;^UTILITY(U,$J,358.3,55018,1,4,0)
 ;;=4^C50.911
 ;;^UTILITY(U,$J,358.3,55018,2)
 ;;=^5001195
 ;;^UTILITY(U,$J,358.3,55019,0)
 ;;=C50.919^^256^2775^121
 ;;^UTILITY(U,$J,358.3,55019,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,55019,1,3,0)
 ;;=3^Malig Neop Female Breast,Unspec Site
 ;;^UTILITY(U,$J,358.3,55019,1,4,0)
 ;;=4^C50.919
 ;;^UTILITY(U,$J,358.3,55019,2)
 ;;=^5001197
 ;;^UTILITY(U,$J,358.3,55020,0)
 ;;=C62.90^^256^2775^159
 ;;^UTILITY(U,$J,358.3,55020,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,55020,1,3,0)
 ;;=3^Malig Neop Testis,Unspec
 ;;^UTILITY(U,$J,358.3,55020,1,4,0)
 ;;=4^C62.90
 ;;^UTILITY(U,$J,358.3,55020,2)
 ;;=^5001236
 ;;^UTILITY(U,$J,358.3,55021,0)
 ;;=D03.9^^256^2775^161
 ;;^UTILITY(U,$J,358.3,55021,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,55021,1,3,0)
 ;;=3^Melanoma in Situ,Unspec
 ;;^UTILITY(U,$J,358.3,55021,1,4,0)
 ;;=4^D03.9
 ;;^UTILITY(U,$J,358.3,55021,2)
 ;;=^5001908
 ;;^UTILITY(U,$J,358.3,55022,0)
 ;;=C45.0^^256^2775^162
 ;;^UTILITY(U,$J,358.3,55022,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,55022,1,3,0)
 ;;=3^Mesothelioma of Pleura
 ;;^UTILITY(U,$J,358.3,55022,1,4,0)
 ;;=4^C45.0
 ;;^UTILITY(U,$J,358.3,55022,2)
 ;;=^5001095
 ;;^UTILITY(U,$J,358.3,55023,0)
 ;;=C90.01^^256^2775^164
 ;;^UTILITY(U,$J,358.3,55023,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,55023,1,3,0)
 ;;=3^Multiple Myeloma,In Remission
 ;;^UTILITY(U,$J,358.3,55023,1,4,0)
 ;;=4^C90.01
 ;;^UTILITY(U,$J,358.3,55023,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,55024,0)
 ;;=C90.00^^256^2775^165
 ;;^UTILITY(U,$J,358.3,55024,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,55024,1,3,0)
 ;;=3^Multiple Myeloma,Not in Remission
 ;;^UTILITY(U,$J,358.3,55024,1,4,0)
 ;;=4^C90.00
 ;;^UTILITY(U,$J,358.3,55024,2)
 ;;=^5001752
 ;;^UTILITY(U,$J,358.3,55025,0)
 ;;=C94.6^^256^2775^166
 ;;^UTILITY(U,$J,358.3,55025,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,55025,1,3,0)
 ;;=3^Myelodysplastic Disease NEC
 ;;^UTILITY(U,$J,358.3,55025,1,4,0)
 ;;=4^C94.6
 ;;^UTILITY(U,$J,358.3,55025,2)
 ;;=^5001846
 ;;^UTILITY(U,$J,358.3,55026,0)
 ;;=D61.82^^256^2775^167
 ;;^UTILITY(U,$J,358.3,55026,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,55026,1,3,0)
 ;;=3^Myelophthisis
 ;;^UTILITY(U,$J,358.3,55026,1,4,0)
 ;;=4^D61.82
 ;;^UTILITY(U,$J,358.3,55026,2)
 ;;=^334037
 ;;^UTILITY(U,$J,358.3,55027,0)
 ;;=D47.9^^256^2775^168
 ;;^UTILITY(U,$J,358.3,55027,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,55027,1,3,0)
 ;;=3^Neop Lymphoid,Hematopoietic & Related Tissue,Uncertain Behavior
 ;;^UTILITY(U,$J,358.3,55027,1,4,0)
 ;;=4^D47.9
 ;;^UTILITY(U,$J,358.3,55027,2)
 ;;=^5002260
 ;;^UTILITY(U,$J,358.3,55028,0)
 ;;=D53.9^^256^2775^172
 ;;^UTILITY(U,$J,358.3,55028,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,55028,1,3,0)
 ;;=3^Nutritional Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,55028,1,4,0)
 ;;=4^D53.9
 ;;^UTILITY(U,$J,358.3,55028,2)
 ;;=^5002298
